Jane Street Group LLC Boosts Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Jane Street Group LLC raised its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 102.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 323,638 shares of the biotechnology company’s stock after purchasing an additional 164,006 shares during the period. Jane Street Group LLC owned 0.20% of Ironwood Pharmaceuticals worth $1,333,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. KBC Group NV raised its position in shares of Ironwood Pharmaceuticals by 59.3% in the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares during the period. Wolverine Trading LLC purchased a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $51,000. Diversified Trust Co bought a new stake in Ironwood Pharmaceuticals during the 3rd quarter valued at $52,000. Legacy Capital Group California Inc. bought a new stake in Ironwood Pharmaceuticals during the 3rd quarter valued at $59,000. Finally, First Dallas Securities Inc. purchased a new stake in shares of Ironwood Pharmaceuticals during the second quarter worth $73,000.

Insider Transactions at Ironwood Pharmaceuticals

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the transaction, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at approximately $1,263,053.76. This trade represents a 3.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Stock Down 3.1 %

Ironwood Pharmaceuticals stock opened at $4.45 on Friday. The business has a 50-day simple moving average of $3.99 and a 200 day simple moving average of $4.84. Ironwood Pharmaceuticals, Inc. has a 52 week low of $3.06 and a 52 week high of $15.70. The stock has a market cap of $712.13 million, a price-to-earnings ratio of -148.33 and a beta of 0.41.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). The business had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.12 EPS. On average, research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on IRWD shares. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.40.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.